Raj Chovatiya

Dr. Raj Chovatiya

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RCRaj Chovatiya
Raj Chovatiya
Amy PallerAmy Paller
Amy Paller

17 January 2023 in JAMA
Verified
Journal Article
Open access
PDF file
RCRaj Chovatiya
Raj Chovatiya
This JAMA Patient Page describes atopic dermatitis (eczema) and its symptoms and treatment options.

10 September 2024 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
CHCarter Haag
Carter Haag
AAAndrew Alexis
Andrew Alexis
VAValeria Aoki
Valeria Aoki
RBRobert Bissonnette
Robert Bissonnette
ABAndrew Blauvelt
Andrew Blauvelt
ESEric L. Simpson
Eric L. Simpson
Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi are not without risk, and their use is not appropriate for all patients with AD, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD. Objectives: To provide a consensus expert opinion statement from the International Eczema Council (IEC) that provides a pragmatic approach to prescribing JAKi, including choosing appropriate patients and dosing, clinical and laboratory monitoring and advice about long-term use. Methods: An international cohort of authors from the IEC with expertise in JAKi selected topics of interest were placed into authorship groups covering 10 subsections. The groups performed topic-specific literature reviews, consulted up-to-date adverse event (AE) data, referred to product labels and provided analysis and expert opinion. The manuscript guidance and recommendations were reviewed by all authors, as well as the IEC Research Committee. Results: We recommend that JAKi be considered for patients with moderate-to-severe AD seeking the benefits of a rapid reduction in disease burden and itch, oral administration and the potential for flexible dosing. Baseline risk factors should be assessed prior to prescribing JAKi, including increasing age, venous thromboembolisms, malignancy, cardiovascular health, kidney/liver function, pregnancy and lactation, and immunocompetence. Patients being considered for JAKi treatment should be current on vaccinations and we provide a generalized framework for laboratory monitoring, although clinicians should consult individual product labels for recommendations as there are variations among the different JAKi. Patients who achieve disease control should be maintained on the lowest possible dose, as many of the observed AEs occurred in a dose-dependent manner. Future studies are needed in patients with AD to assess the durability and safety of continuous long-term JAKi use, combination medication regimens and the effects of flexible, episodic treatment over time. Conclusions: The decision to initiate JAKi treatment should be shared between the patient and provider, accounting for AD severity and personal risk–benefit assessment, including consideration of baseline health risk factors, monitoring requirements and treatment costs.

4 October 2019 in Children
Verified
Journal Article
Open access
PDF file
RCRaj Chovatiya
Raj Chovatiya
JSJonathan Silverberg
Jonathan Silverberg
Atopic dermatitis (AD) and psoriasis are chronic inflammatory skin diseases associated with a significant cutaneous and systemic burden of disease as well as a poor health-related quality of life. Here, we review the complex pathophysiology of both AD and psoriasis and discuss the implications for treatment with current state-of-the-art and emerging topical and systemic therapies. Both AD and psoriasis are caused by a complex combination of immune dysregulation, skin-barrier disruption, genetic factors, and environmental influences. Previous treatments for both diseases were limited to anti-inflammatory agents that broadly suppress inflammation. Emerging insights into relevant pathways, including recognition of the role of T-helper type 2 driven inflammation in AD and T-helper 1 and 17 driven inflammation in psoriasis, have led to a therapeutic revolution. There are a number of novel treatment options available for AD and psoriasis with many more currently under investigation.

14 December 2020 in Dermatitis®
Verified
Journal Article
Open access
WBWendy Mbs Smith Begolka
Wendy Mbs Smith Begolka
RCRaj Chovatiya
Raj Chovatiya
ITIsabelle J. Thibau
Isabelle J. Thibau
JSJonathan Silverberg
Jonathan Silverberg
Background Atopic dermatitis (AD) is associated with considerable financial cost. However, the full burden of out-of-pocket (OOP) expenses is not well understood. Objective We sought to characterize the OOP health care expenses associated with AD management. Methods A 25-question voluntary online survey was administered to National Eczema Association members worldwide (n = 113,502). Inclusion criteria (US residents age ≥18 years who either self-reported had AD or were primary caregivers of individuals with AD) were met by 77.3% (1118/1447) of respondents. Results Respondents reported OOP expenses in 3 categories: (1) health care providers and prescriptions, including health care provider visit deductibles (68.7% [686]), prescription co-pays (64.3% [635]), and prescriptions not covered by insurance (48.6% [468]); (2) nonprescription health care products, including moisturizers (94.3% [934]), hygiene products (85.0% [824], allergy medications (75.1% [715]), itch relievers (68.25% [647]), dietary supplements (52.2% [491]), and sleep aids (37.0% [336]); and (3) complementary approaches, including cleaning products (74.7% [732]), clothing/bedding (44.8% [430]), alternative medications (19.0% [180]), and adjunctive therapies (15.9% [150]). The median annual AD OOP expense was US $600 (range, US $0–$200,000), with 41.9% (364) reporting expenditures US $1000 or greater. Conclusions Out-of-pocket expenses place a significant financial burden on individuals with AD. Additional studies are needed to better understand associations and impact of OOP costs.

1 January 2022 in Journal Of Drugs In Dermatology
Verified
Journal Article
Closed access
RCRaj Chovatiya
Raj Chovatiya
JSJonathan Silverberg
Jonathan Silverberg
Background: Recent advances were made in characterizing the clinical heterogeneity of atopic dermatitis (AD). Objective: To review the clinical domains contributing to AD heterogeneity and describe their importance in clinical practice. Methods: We conducted a focused review of the published literature, including retrospective, observational, and prospective studies, clinical trials, and consensus guidelines. Results: AD is associated with heterogeneous skin manifestations, symptoms, lesional severity, lesional extent, longitudinal course, burden of signs and symptoms, and comorbidities. Each of these domains characterizes a different aspect of AD and should be used to guide overall severity assessment and clinical management. Primary focus on any one specific clinical domain of AD is insufficient to describe the full burden of disease. Conclusion: Heterogeneity should be routinely considered during AD clinical encounters. J Drugs Dermatol. 2022;21(2):172-176. doi:10.36849/JDD.6408Atopic Dermatitis